粪便细菌移植与肝脏疾病的研究进展  

Research Progress of Fecal Microbiota Transplantation and Liver Disease

作　　者：王威巍[1] 张宇[1] 李靖[1] 

机构地区：[1]第三军医大学第二附属医院肝胆外科,重庆400037

出　　处：《医学综述》2017年第6期1161-1165,共5页Medical Recapitulate

摘　　要：粪便细菌移植作为一种全新的治疗方式,其临床应用价值越来越受到重视,并且在某些疾病,如消化道疾病及自身免疫性疾病的治疗方面表现出独特的优势。但由于其伦理学争议以及患者的心理接受能力,临床应用仍受到较大的限制。而且由于移植物独特的来源,对其研究也仅处于起步阶段,特别是有关其机制、治疗标准、适应证及禁忌证等均无定论。同时,对于其是否会引起其他并发症或者传染病以及应对措施,目前仍未达成相应的共识。Fecal microbiota transplantation as a new way of treatment,is drawing more and more attention on its clinical application,and has presented unique advantages in the treatment of some diseases such as digestive tract disease and autoimmune disease. But because of its ethical controversy,and the patient’ s psychological acceptance,clinical application is still largely limited. And due to the source of the unique graft,very little research is done,especially its mechanism,treatment standard,indications and contraindications are inconclusive,the research is only in its infancy. Meanwhile,there is still no consensus on whether it can cause other complications or infectious diseases as well as the corresponding measures.

关 键 词：粪便细菌移植 肝性脑病 肝脏 肠道菌群 

分 类 号：R575.2[医药卫生—消化系统]